Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Chief R&D Officer | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEKTAR THERAPEUTICS
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,570 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Sale · Disposed 186 · Balance 9,570 F1: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2: This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
F2: This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 20, 2026 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 186 | $71.98 | $13,388.28 |
DisclosureSEC source: 0001193125-26-359588 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,570 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 24, 2026 Filed Jul 24, 2026 22:35 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 16,500 | $0.00 Strike: $15.15 | $0.00 |
DisclosureSEC source: 0001193125-26-316458 · ownership.xml · derivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2032-12-12 F1 · security: These stock options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of five years from the date of grant. F2 · derivative.exercise_date: The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 23, 2026 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on July 24, 2026 (subject to remaining time-based vesting requirements). Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,681 | $70.00 | $397,670.00 |
DisclosureSEC source: 0001193125-26-295112 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,756 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 23:12 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,538 | $60.71 | $336,211.98 |
DisclosureSEC source: 0001193125-26-274534 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,437 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F2 · price: This transaction was executed in multiple trades at prices ranging from $60.06 to $61.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 19, 2026 Filed May 21, 2026 22:26 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 199 | $65.51 | $13,036.49 |
DisclosureSEC source: 0001193125-26-235030 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,975 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $64.88 to $68.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 18, 2026 Filed Feb 21, 2026 00:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 180 | $73.00 | $13,140.00 |
DisclosureSEC source: 0001193125-26-061886 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,174 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $72.51 to $74.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 00:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,867 | $35.67 | $137,935.89 |
DisclosureSEC source: 0001193125-26-019843 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,354 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.17 to $36.23 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 23:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 25,000 | $0.00 Strike: $43.48 | $0.00 |
DisclosureSEC source: 0001193125-25-331189 · ownership.xml · derivative · entry 2 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-12-21 F2 · derivative.exercise_date: Stock options vest over four years from the date of grant, (December 22, 2025) in substantially equal monthly installments based on continued service. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 23:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-331189 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,221 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs vest over four years from the date of grant (December 22, 2025) in substantially equal quarterly installments based on continued service. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 01:30 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,157 | $54.28 | $62,801.96 |
DisclosureSEC source: 0001193125-25-297855 · ownership.xml · nonDerivative · entry 2 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,971 F3 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $58.26 to $59.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 21, 2025 Filed Nov 26, 2025 01:30 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 4,766 | $0.00 Strike: $281.25 | $0.00 |
DisclosureSEC source: 0001193125-25-297855 · ownership.xml · derivative · entry 3 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,766 Underlying: Common Stock · 4,766 shares Expires 2028-12-17 F5 · security: These stock options were granted on December 18, 2020 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of four years from the date of grant. F6 · derivative.exercise_date: The Compensation Committee determined on November 20, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on November 21, 2025. Read SEC document |
| November 21, 2025 Filed Nov 26, 2025 01:30 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 2,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-297855 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,128 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 18, 2020 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 20, 2025 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on November 21, 2025. Read SEC document |
| September 04, 2025 Filed Sep 9, 2025 00:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 307 | $35.69 | $10,956.83 |
DisclosureSEC source: 0000950170-25-113692 · ownership.xml · nonDerivative · entry 4 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,462 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $35.48 to $36.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 04, 2025 Filed Sep 9, 2025 00:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 189 | $34.41 | $6,503.49 |
DisclosureSEC source: 0000950170-25-113692 · ownership.xml · nonDerivative · entry 3 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,769 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $34.09 to $34.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 04, 2025 Filed Sep 9, 2025 00:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 432 | $33.60 | $14,515.20 |
DisclosureSEC source: 0000950170-25-113692 · ownership.xml · nonDerivative · entry 2 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,958 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.08 to $34.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 04, 2025 Filed Sep 9, 2025 00:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 793 | $32.43 | $25,716.99 |
DisclosureSEC source: 0000950170-25-113692 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,390 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.08 to $33.02 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 02, 2025 Filed Sep 5, 2025 01:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 485 | $30.10 | $14,598.50 |
DisclosureSEC source: 0000950170-25-113130 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,183 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.28 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 19, 2025 Filed Aug 22, 2025 01:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 16,666 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000950170-25-110775 · ownership.xml · derivative · entry 2 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 16,666 shares Expires 2031-12-12 F4 · security: These stock options were granted on December 13, 2023 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of three years from the date of grant. F5 · derivative.exercise_date: The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 17, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on August 19, 2025 (subject to remaining time-based vesting requirements). Read SEC document |
| August 19, 2025 Filed Aug 22, 2025 01:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 725 | $26.59 | $19,277.75 |
DisclosureSEC source: 0000950170-25-110775 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,668 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.19 to $27.15 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. Read SEC document |
| May 19, 2025 Filed May 22, 2025 00:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 10,712 | $0.67 | $7,177.04 |
DisclosureSEC source: 0000950170-25-075979 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,892 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.66 to $0.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 23:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 10,300 | $1.01 | $10,403.00 |
DisclosureSEC source: 0000950170-25-025043 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,604 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.00 to $1.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 19, 2024 Filed Dec 21, 2024 01:33 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 51,115 | $0.94 | $48,048.10 |
DisclosureSEC source: 0000950170-24-139242 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 326,904 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $.89 to $1.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 01:55 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 375,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0000950170-24-137545 · ownership.xml · derivative · entry 3 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2032-12-12 F5 · derivative.exercise_date: Stock options vest over four years from the date of grant, (December 13, 2024) in equal monthly installments based on continued service. Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 01:55 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 270,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0000950170-24-137545 · ownership.xml · derivative · entry 2 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2030-08-14 F3 · security: These stock options were granted on August 15, 2022 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of three years from the date of grant. F4 · derivative.exercise_date: The Compensation Committee determined on November 18, 2024 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on December 13, 2024 (subject to remaining time-based vesting requirements). Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 01:55 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 135,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-137545 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 378,019 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on August 15, 2022 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 18, 2024 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on December 13, 2024 (subject to remaining time-based vesting requirements). Read SEC document |
| November 19, 2024 Filed Nov 21, 2024 01:37 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 7,785 | $1.01 | $7,862.85 |
DisclosureSEC source: 0000950170-24-129463 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,019 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.00 to $1.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 01:15 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 6,866 | $1.28 | $8,788.48 |
DisclosureSEC source: 0000950170-24-099354 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,804 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.24 to $1.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 17, 2024 Filed May 21, 2024 01:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 7,355 | $1.75 | $12,871.25 |
DisclosureSEC source: 0000950170-24-062645 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,670 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.72 to $1.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 20, 2024 Filed Feb 23, 2024 01:19 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 9,014 | $0.68 | $6,129.52 |
DisclosureSEC source: 0000950170-24-019045 · ownership.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,025 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.66 to $0.71. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 23:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 250,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001209191-23-058861 · doc4.xml · derivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-12-12 F1 · derivative.exercise_date: This stock option vests over three years from the date of grant, (December 13, 2023) in equal monthly installments based on continued service. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 02:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 9,646 | $0.49 | $4,726.54 |
DisclosureSEC source: 0001209191-23-056184 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,039 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.47 to $0.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 00:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 9,703 | $0.78 | $7,568.34 |
DisclosureSEC source: 0001209191-23-046462 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,685 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.75 to $0.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 16, 2023 Filed May 18, 2023 00:29 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 9,791 | $0.72 | $7,049.52 |
DisclosureSEC source: 0001209191-23-030448 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,388 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.71 to $0.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 16, 2023 Filed Feb 18, 2023 02:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 10,484 | $3.00 | $31,452.00 |
DisclosureSEC source: 0001209191-23-010956 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,179 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.94 to $3.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 13,460 | $3.57 | $48,052.20 |
DisclosureSEC source: 0001209191-22-057968 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,663 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.42 to $3.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 22:27 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 73,716 | $4.65 | $342,779.40 |
DisclosureSEC source: 0001209191-22-046909 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,123 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $4.56 to $4.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the Issuer. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 23:41 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 10,560 | $4.76 | $50,265.60 |
DisclosureSEC source: 0001209191-22-046489 · doc4.xml · nonDerivative · entry 2 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,839 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $4.67 to $4.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 23:41 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock · Derivative | 270,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001209191-22-046489 · doc4.xml · derivative · entry 3 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2030-08-14 F4 · security: Stock options were granted in connection with a retention program and are in lieu of the Issuer's usual end-of-year annual performance grants. F5 · derivative.exercise_date: Stock options vest over three years from the date of grant in substantially equal monthly installments based on continued service. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 23:41 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 135,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046489 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,399 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted in connection with a retention program and are in lieu of the Issuer's usual end-of-year annual performance grants. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service. Read SEC document |
| May 16, 2022 Filed May 18, 2022 01:40 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 21,673 | $3.95 | $85,608.35 |
DisclosureSEC source: 0001209191-22-029905 · doc4.xml · nonDerivative · entry 2 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,399 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 15, 2022 Filed May 18, 2022 01:40 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 23,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-029905 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,072 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 14, 2018 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on May 13, 2022. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (May 15, 2022) following the date that the performance-based vesting requirement was satisfied. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 23:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 10,912 | $10.95 | $119,486.40 |
DisclosureSEC source: 0001209191-22-011442 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,122 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.77 to $11.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 01:28 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 94,000 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001209191-21-070697 · doc4.xml · derivative · entry 2 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,000 Underlying: Common Stock · 94,000 shares Expires 2029-12-15 F2 · derivative.exercise_date: This stock option vests over four years from the date of grant in equal monthly installments based on continued service. Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 01:28 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 52,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070697 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,034 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 23:11 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 20,869 | $13.16 | $274,636.04 |
DisclosureSEC source: 0001209191-21-065229 · doc4.xml · nonDerivative · entry 2 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,084 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $12.84 to $13.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:11 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 40,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065229 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,953 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 12, 2019 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on September 15, 2021. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (November 15, 2021) following the date that the performance-based vesting requirement was satisfied. Read SEC document |
| October 12, 2021 Filed Oct 15, 2021 01:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 71,550 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0001209191-21-060513 · doc4.xml · derivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,550 Underlying: Common Stock · 71,550 shares Expires 2027-12-11 F1 · security: These stock options were granted on December 12, 2019 under the Company's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Company determined that the performance-based vesting requirement for these stock options was satisfied on September 15, 2021. Pursuant to the terms of the 2017 Plan, these stock options vested on the next monthly vesting date (October 12, 2021) following the date that the performance-based vesting requirement was satisfied. F3 · derivative.exercise_date: These stock options vest on a monthly pro-rata basis over a period of four years from the grant date (December 12, 2019). Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 23:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 7,662 | $13.83 | $105,965.46 |
DisclosureSEC source: 0001209191-21-052395 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,803 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.69 to $14.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: Since the date of the last ownership report of the reporting person, he transferred 14,600 shares of NKTR common stock to his ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-spouse. Read SEC document |
| May 17, 2021 Filed May 19, 2021 23:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 31,111 | $18.30 | $569,331.30 |
DisclosureSEC source: 0001209191-21-034191 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,065 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.95 to $18.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 24,141 | $22.37 | $540,034.17 |
DisclosureSEC source: 0001209191-21-012128 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,176 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.04 to $22.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.